Trial Profile

A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 15 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Magrolimab (Primary) ; Pivekimab sunirine (Primary) ; Venetoclax (Primary)
Indications Acute myeloid leukaemia
Focus Adverse reactions; Therapeutic Use
Sponsors AbbVie; ImmunoGen

Most Recent Events

02 Dec 2025 According to a Abbvie media release, data from this trial will be presented at the 2025 American Society of Hematology (ASH) Congress.
02 Dec 2025 Results presented in the Abbvie media release.
24 Feb 2025 Planned End Date changed from 1 Apr 2026 to 1 Feb 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com